Jefferies Reiterates Bullish View on Celgene (CELG) Following Talk

Jefferies analyst Brian Abrahams reiterated a Buy rating and $141 price target on Celgene (NASDAQ: CELG) after hosting President of Research & Early Dev, Dr. Tom Daniel, M.D, on the 2nd call of their Speaking the Science series.

"Overall, we came away optimistic CELG has numerous high-quality shots on goal within its early portfolio - most of which are not currently in our or the Street’s models even on a probability-weighted basis - which as they mature could increase confidence in CELG’s ability to maintain meaningful revenues after the Revlimid patent cliff and drive share appreciation," Abrahams commented.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $109.45 yesterday.

You May Also Be Interested In

• CFRA Upgrades Infosys Technologies (INFY) to Buy
• Morgan Stanley Upgrades Sea Ltd. (SE) to Overweight
• Synovus Financial (SNV) PT Lowered to $38 at Keefe, Bruyette & Woods